MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyae085

Медицинская библиотека · The oncologist · 2024

Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.

Connell Emily, Gerard Émilie, Oules Bénédicte, Brunet-Possenti Florence, Lamoureux Anouck, Bonnefille Hugo, Mary-Prey Sorilla, Carrasquilla Ana, Mouret Stéphane, Kramkimel Nora, Lesage Candice, Stoebner Pierre-Emmanuel, Bartoli Axel, Monestier Sandrine, Correard Florian, Gros Audrey, Jeanson Arnaud, Ouafik L'Houcine, Gaudy-Marqueste Caroline, Tomasini Pascale, Charles Julie, Amini-Adle Mona, Malissen Nausicaa

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Only a fraction of patients with metastatic melanoma derive durable benefit from approved treatments. The clinical impact of personalized medicine strategies for melanoma, apart from BRAF, NRAS, or CKIT targeting, has rarely been reported.

MATERIALS AND

METHODS

By means of the Group of Cutaneous Oncology of the French Society of Dermatology, we retrospectively included all patients with advanced melanoma aged 18 years and older for whom molecular testing identified one or more actionable molecular alterations and who accordingly received molecularly matched therapy. We excluded patients with only BRAF, NRAS, or CKIT alterations and patients who received molecularly matched therapy for less than 15 days.

RESULTS

We included 26 patients with a median follow-up of 8 months (1-54), a median age of 63 years (24-89), and a sex ratio of 2.7. These patients had been heavily pretreated, and 64% had elevated LDH levels. The disease control rate was 38%, with 4 cases of partial response (overall response rate: 15%) and 6 of stable disease for at least 6 months. The median duration of treatment was 3.1 months (0.9-13.5). Among patients with disease control, the median duration of control was 6.6 months (2.6-13.5) and 3 cases were ongoing at the end of the study. Patients with controlled disease had GNA11, MAP2K1, FYCO1-RAF1, HRAS, ATM, CCND1, MDM2/CDK4, and CDKN2A/NRAS alterations.

CONCLUSIONS

High-throughput sequencing followed by matched targeted therapy is a promising approach for patients with advanced melanoma refractory to approved treatments.

Для цитирования: Connell Emily, Gerard Émilie, Oules Bénédicte, Brunet-Possenti Florence, Lamoureux Anouck, Bonnefille Hugo, Mary-Prey Sorilla, Carrasquilla Ana, Mouret Stéphane, Kramkimel Nora, Lesage Candice, Stoebner Pierre-Emmanuel, Bartoli Axel, Monestier Sandrine, Correard Florian, Gros Audrey, Jeanson Arnaud, Ouafik L'Houcine, Gaudy-Marqueste Caroline, Tomasini Pascale, Charles Julie, Amini-Adle Mona, Malissen Nausicaa. Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.. The oncologist. 2024. DOI: 10.1093/oncolo/oyae085.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.